Wood Mark Form 4 October 26, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or

Form 5 obligations may continue. See Instruction STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

1. Name and Address of Reporting Person * Wood Mark

2. Issuer Name and Ticker or Trading Symbol

BIOMARIN PHARMACEUTICAL

INC [BMRN]

3. Date of Earliest Transaction (Month/Day/Year)

10/24/2011

5. Relationship of Reporting Person(s) to

Issuer

below)

(Check all applicable)

VP, Human Resources

10% Owner

_ Other (specify

OMB

Number:

Expires:

response...

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

C/O BIOMARIN

(Last)

PHARMACEUTICAL INC., 105 **DIGITAL DRIVE**

(Street)

(First)

(Middle)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Director

X_ Officer (give title

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

NOVATO, CA 94949

(City)	(State)	(Zip) Tab	le I - Non-	Derivativ	e Secu	rities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securionor Dispo (Instr. 3,	sed of 4 and (A) or	` '	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/24/2011(1)	10/24/2011	M	83	A	\$ 17.86	20,717	D	
Common Stock	10/24/2011(1)	10/24/2011	M	937	A	\$ 14.39	21,654	D	
Common Stock	10/24/2011(1)	10/24/2011	M	833	A	\$ 21.51	22,487	D	
Common Stock	10/24/2011(1)	10/24/2011	S	1,853	D	\$ 33.3243 (2)	20,634	D	

Edgar Filing: Wood Mark - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	o ro f Derivative	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to bu) Common Stock	\$ 17.86	10/24/2011 <u>(1)</u>	10/24/2011	M	83	06/17/2009 <u>(3)</u>	12/16/2018	Common Stock	83
Stock Option (right to buy) Common Stock	\$ 14.39	10/24/2011 <u>(1)</u>	10/24/2011	M	937	11/12/2009 <u>(4)</u>	05/11/2019	Common Stock	937
Stock Option (right to buy) Common Stock	\$ 21.51	10/24/2011 <u>(1)</u>	10/24/2011	M	833	11/12/2010 ⁽⁵⁾	05/11/2020	Common Stock	833

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Wood Mark			VP, Human Resources			
C/O BIOMARIN PHARMACEUTICAL INC.						

Reporting Owners 2

Deletionships

105 DIGITAL DRIVE NOVATO, CA 94949

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact

10/26/2011

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading plan executed on August 20, 2011.
- The price in Column 4 is a weighted average price. The prices actually received ranged from \$32.99 to \$33.47. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at
- (2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Original option grant vests 6/48th on June 17, 2009 and 1/48th each on the 17th of each month thereafter.
- (4) Original option grant vests 6/48th on November 12, 2009 and 1/48th each on the 12th of each month thereafter.
- (5) Original option grant vests 6/48th on November 12, 2010 and 1/48th each on the 12th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays

a currently valid OMB number.

Signatures 3